GlycoMimetics's lead anti-inflammatory compound, GMI-1070, is in Phase 2 clinical trials evaluating its use in patients with vaso-occlusive crisis of sickle cell disease. The drug inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.
GlycoMimetics has a family of compounds targeting the overlapping pathways of E-selectin and CXCR4. These compounds hold promise for treatment of blood cancers and certain inflammatory conditions.
